TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01368081

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin tablets 500-2250 mg a day (twice or three times per day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 low dose tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (low dose)
Description: Placebo tablets once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 high dose tablet once daily
Study: NCT04534764

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A with cosmetic pattern
Description: TEST

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1-Day Acuvue DEFINE Vivid Style
Description: CONTROL

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1-Day Acuvue DEFINE Vivid Style
Description: CONTROL
Study: NCT01136304

Intervention type: DRUG
Intervention: Imiglucerase
Description: Imiglucerase intravenous infusions regardless of dose or schedule of administration.
Study: NCT02659020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaratumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaratumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaratumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered IV
Study: NCT03204175

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparator arm
Description: This is the same intervention as FIT Plus, but will be delivered to schools following endline data collection
Study: NCT03093532

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ED SBIRT-HTN
Description: Participants in the ED-SBIRT-HTN group will receive the following interventions:~1) screening (risk assessment/stratification), 2) a limited bedside echocardiogram (looking for evidence of subclinical cardiac disease), and 3) a urine microalbumin test (marker of early cardiovascular disease).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ED SBIRT-HTN
Description: Participants in the ED-SBIRT-HTN group will receive the following interventions:~1) screening (risk assessment/stratification), 2) a limited bedside echocardiogram (looking for evidence of subclinical cardiac disease), and 3) a urine microalbumin test (marker of early cardiovascular disease).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PACHT-c
Description: Participants randomized to the SBIRT-HTN +PACHT-c (Post-Acute Care Hypertension Transition Clinic) arm will receive all interventions of the ED SBIRT-HTN arm plus a 48-72 hour follow-up in the Post-Acute Care Hypertension Transition Clinic for repeat blood pressure assessment, review of screening assessments, and secured PCP appointment with a federally qualified health center within the study site's health system.
Study: NCT01942525

Intervention type: OTHER
Intervention: aEEG
Description: The amplitude integrated EEG was performed using a single-channel, biparietal aEEG (CFM 6000; Natus Medical Incorporated, San Carlos, CA)

Intervention type: OTHER
Intervention: aEEG
Description: The amplitude integrated EEG was performed using a single-channel, biparietal aEEG (CFM 6000; Natus Medical Incorporated, San Carlos, CA)
Study: NCT01368081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (high dose)
Description: Placebo tablets once daily
Study: NCT04429698

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Point of care ultrasonography
Description: Point-of-care Ultrasonography is an imaging method performed with ultrasound aid to facilitate rapid diagnosis and interventions during emergency intervention.
Study: NCT00483938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated-interferon Alfa-2a
Description: Participants will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for the specified duration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated-interferon Alfa-2a
Description: Participants will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for the specified duration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated-interferon Alfa-2a
Description: Participants will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for the specified duration.
Study: NCT01117285

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3-day post-graduate course
Description: A 3-day course in using the COTiD program in clinical practice. The 3 days are not provided uninterrupted but there are at least two weeks between each day to provide time to practice with the guideline (for discussion on the 2nd day).~The course consists of theory on the content of the guideline and its effectiveness, Practice parts of the guideline by rol playing, and discussing each others skills through watching video material.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined implementation strategy
Description: The combined implementation strategy provides strategies for occupational therapists (OTs), physicians, and managers.~OTs receive:~* 3-day post-graduate course~* 2 extra training days: Lectures and skills practice focused on using the COTiD program and promoting the use of the program within their organization and network.~* Coaching on the job: Barriers to using the COTiD program in practice are discussed using motivational interviewing.~* Discussion platform~* Web-based registration system: Provides guidance in using the COTiD program for every individual client.~* Regional meetings: successes and difficulties in using the COTiD are discussed.~Managers and physicians receive:~* Information on the COTiD program through a website and newsletters.~* Motivational reminders.
Study: NCT02529605

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Product B® IsaGenesis®
Description: This will be a crossover comparison of a one time dose of the liquid-gel formulation contained in 2 capsules; 1280 mg/capsule.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Product B® IsaGenesis®
Description: This will be a crossover comparison of a one time dose of the liquid-gel formulation contained in 2 capsules; 1280 mg/capsule.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: IsaGenesis®
Description: This will be a crossover comparison of a one time dose of the dried powder extract contained in 2 capsules; 1070 mg /capsule.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: IsaGenesis®
Description: This will be a crossover comparison of a one time dose of the dried powder extract contained in 2 capsules; 1070 mg /capsule.
Study: NCT02769130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Losartan is given for 12 months
Study: NCT02162823

Intervention type: PROCEDURE
Intervention: Pancreatic Surgery
Description: Surgical removal of the pancreatic tumour (cancer) in the intervention group
Study: NCT01792505

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell Vaccine in combination with Imiquimod cream
Description: After a successful complete resection of malignant glioma, patients will receive a total of 3 vaccines, each are 2 weeks apart. Imiquimod cream will be applied prior to and after each vaccination.
Study: NCT03511599

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Single-pulse transcranial magnetic stimulation and theta-burst stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: Single-pulse transcranial magnetic stimulation and theta-burst stimulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo tablet matched to cycloserine tab
Study: NCT01284010

Intervention type: GENETIC
Intervention: DNA analysis
Study: NCT02659020

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study: NCT02035852

Intervention type: OTHER
Intervention: MRI
Description: 3T MRI vs. 7T MRI
Study: NCT04440956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-SARTATE
Description: 200MBq of 64Cu-MeCOSar-Octreotate (64Cu-SARTATE) given as a single bolus intravenous injection and peptide mass will not exceed 10micrograms.
Study: NCT02901951

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix-B
Description: Intramuscular administration of single challenge dose of Engerix-B vaccine in the deltoid region of the non-dominant arm.
Study: NCT01971853

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oral placebo
Description: Ibuprofen placebo and Acetaminophen placebo will be added to a Demerol-Vistaril regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Analgesics
Description: Ibuprofen at 5.0 mg/kg and Acetaminophen at 15.0 mg/kg will be added to a Demerol-Vistaril regimen
Study: NCT01944774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemonoxacin 500 mg
Description: IV Infusion, once daily for 7\~14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemonoxacin 650 mg
Description: IV Infusion, once daily for 7\~14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400 mg
Description: IV Infusion, once daily for 7\~14 days
Study: NCT01351675

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, once daily
Study: NCT01284010

Intervention type: GENETIC
Intervention: fluorescence in situ hybridization

Intervention type: GENETIC
Intervention: gene expression analysis

Intervention type: GENETIC
Intervention: microarray analysis

Intervention type: GENETIC
Intervention: mutation analysis

Intervention type: GENETIC
Intervention: polymerase chain reaction

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Study: NCT03893643

Intervention type: OTHER
Intervention: no intervention
Description: no intervention in an observational study
Study: NCT01027598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib: 600 mg orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib: 150 mg orally daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Erlotinib
Description: Erlotinib: 150 mg orally daily
Study: NCT01351675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone Methyl: 20 mg
Description: 20 mg, oral, once daily
Study: NCT01039909

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For the placebo product, SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.~Eight size 00 Swedish orange opaque hard gelatin capsules containing placebo are stored in a dosing bottle and provided to all participating subjects for oral ingestion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SRT2104
Description: SRT2104 investigational product is a size 00 Swedish Orange opaque hard gelatin capsule containing 0.25 g of SRT2104, a new chemical entity which is supplied as a micronized, yellowish/amber powder. Eight SRT2104 capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion.
Study: NCT00483938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated-interferon Alfa-2a
Description: Participants will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for the specified duration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated-interferon Alfa-2a
Description: Participants will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for the specified duration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated-interferon Alfa-2a
Description: Participants will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for the specified duration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated-interferon Alfa-2a
Description: Participants will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for the specified duration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Participants will receive ribavirin 1000 to 1400 mg orally daily for the specified duration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Participants will receive ribavirin 1000 to 1400 mg orally daily for the specified duration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Participants will receive ribavirin 1000 to 1400 mg orally daily for the specified duration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Participants will receive ribavirin 1000 to 1400 mg orally daily for the specified duration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Participants will receive ribavirin 1000 to 1400 mg orally daily for the specified duration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Participants will receive ribavirin 1000 to 1400 mg orally daily for the specified duration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Participants will receive ribavirin 1000 to 1400 mg orally daily for the specified duration.
Study: NCT02493231

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nefopam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study: NCT01710631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eszopiclone 3 mg
Description: eszopiclone 3 mg (comprised of either two 1.5 mg tablets, or one 1 mg tablet and one 2 mg tablet).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT03945149

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Turmipure Gold™
Description: 30 subjects will take 1000mg in 4 capsules (with 250ml water before breakfast , each day, during 5 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 30 subjects will take 4 capsules with 250ml water before breakfast , each day, during 5 weeks
Study: NCT03691571

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal Cooling
Description: The EnsoETM is a non-sterile multi-lumen silicone tube placed in the esophagus for the purpose of cooling or warming a patient while simultaneously allowing gastric decompression and drainage.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard of care involves standard temperature probe monitoring.
Study: NCT02481817

Intervention type: PROCEDURE
Intervention: Endoscopic dilation of subglottic stenosis
Description: This is accomplished with rigid instruments or inflatable balloons.

Intervention type: PROCEDURE
Intervention: Endoscopic resection of the stenosis
Description: This is accomplished with C02 lasers and paired with prolonged medical therapy after surgery.

Intervention type: PROCEDURE
Intervention: Tracheal Resection
Description: Resection of the affected tracheal segment with end-to-end anastomosis
Study: NCT01643824

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Therapy
Description: - Prescription dose to PTV as according to the following dose escalation schema: Arml 1: 60 GyE /10 fx, 6GyE fraction dose, 5 days/week, for HCC free from the alimentary tract (i.e., stomach, duodenum, esophagus, small and large bowel) (more than 2cm from clinical target volume), TLV30 \<40%, and/or RLV30 \<30%) Arm 2: 50 GyE /10 fx, 5GyE fraction dose, 5 days/week, for HCC close to the alimentary tract (less than 2cm from clinical target volume) but not contact with the alimentary tract, TLV30\<50% and RLV30\<40% Arm 3: 35 GyE /10 fx, 4GyE fraction dose, 5 days/week, for HCC contact to the alimentary tract (contact with clinical target volume), TLV30\<60%, and/or RLV30\<50%~- Dose prescription : 95% isodose volume of prescribed dose encompassed PTV
Study: NCT02831517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB074
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB074
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched Placebo
Study: NCT01278797

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan/Amlodipine Combination Tablet
Description: Combination Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine Monocomponent
Description: Active Comparator
Study: NCT04326049

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LLETZ with videocolposcope
Description: Loop procedure using a videocolposcope in order to see and remove the abnormal cervical tissue

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LLETZ with binocular colposcope
Description: Loop procedure using a binocular colposcope in order to see and remove the abnormal cervical tissue
Study: NCT01258283

Intervention type: OTHER
Intervention: Addional imaging
Description: All patients will systematically have an 18F-FDG PET-CT (18F-fluorodeoxyglucose positron emission tomography/computed tomography) and a 123MIBG (Iodine 123 metaiodobenzylguanidine) scintigraphy
Study: NCT00839761

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: iron fortified rice

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: iron drops
Study: NCT00856804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Open-label pilot study analyzing the impact of adding thalidomide (200 mg/d)to SOC on 12 weeks virological response in patients with chronic hepatitis C and interferon resistance.
Study: NCT00496288

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prophylactic radiation to the contralateral breast
Description: The contralateral breast will be treated with 2 tangent fields, using 1.8-2 Gy/fx to a total dose of 50-50.4 Gy. The whole breast will be treated according to traditional guidelines and as described in the RTOG/NSABP B39 study. The heart should be maximally blocked for left sided breasts, included lung tissue should be reduced to minimum. No overlapping field is allowed on the skin between the two breast fields in the midline. Maximal dose should not exceed 110%
Study: NCT01726985

Intervention type: OTHER
Intervention: Parameter Based Clinical Disposition
Description: Parameter Based Clinical Disposition'~Physicians will initiate / titrate medications and obtain consults as usual but are highly encourage to keep patients in the hospital until at least 2 of the following 3 criteria are met:~* NT-ProBNP reduction of \> 23% from peak value during admission~* Fluid Reduction of \> 1.3L (orders for I/O q8h required)~* Serum Sodium of \> 135 mmol/L the day of planned discharge
Study: NCT03300063

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low flow nocturnal oxygen
Description: Nocturnal low-flow oxygen via nasal cannula
Study: NCT03238833

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: luteal ovarian stimulation
Description: In the in vitro fertilization cycle, controlled ovarian stimulation was started since the luteal phase.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: follicular ovarian stimulation
Description: In the in vitro fertilization cycle, controlled ovarian stimulation was started since the follicular phase.
Study: NCT02518373

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G17DT
Description: G17DT is a therapeutic immunogen, formulated as a white, sterile, semi-viscous, water-in-oil emulsion (30:70 weight for weight). It was manufactured and supplied by Nova Laboratories Ltd., in glass ampoules containing 0.5 mL at a concentration of 1.25 mg/mL, as a single dose to be administered by intramuscular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Proton pump inhibitor used in the treatment of dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, laryngopharyngeal reflux, and Zollinger-Ellison syndrome.
Study: NCT02624531

Intervention type: DRUG
Group type: OTHER
Intervention: Taxane
Description: NACT and Fertility-sparing Treatment Strategy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: radical trachelectomy
Description: NACT and Fertility-sparing Treatment Strategy
Study: NCT01755728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Per gavage paracetamol 15 mg/kg every 6 hours, for up to 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Per Gavage ibuprofen 10mg/kg x 3/d for up to 5 days Gold standard per literature
Study: NCT01417481

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glycine
Description: Daily oral supplement of glycine at a dose of 0.5 g/kg divided in three doses during 8 weeks
Study: NCT01755728

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closure of PDA
Description: Open surgery for closure of PDA
Study: NCT02701933

Intervention type: DRUG
Group type: OTHER
Intervention: Ketamine
Description: Racemic ketamine, intravenous, at a concentration of 10mg ketamine per 50ml infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Ketamine
Description: Racemic ketamine, intravenous, at a concentration of 10mg ketamine per 50ml infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Saline
Description: Saline, intravenous infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Saline
Description: Saline, intravenous infusion
Study: NCT02492321

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EBI-005

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Study: NCT05191927

Intervention type: OTHER
Intervention: male
Description: Nine preoperative predictors were identified for the nomogram: gender, age, platelet counts, TPOAb level and US signatures including maximum diameter, boundary, component, calcification and cervical lymph node enlargement.
Study: NCT03486067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-93269
Description: Specified dose on specified days